TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00507000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Drug: Cholecalciferol Drug: Cholecalciferol 60,000 IU sachet and calcium carbonate Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate for first two months followed by 1 gm of elemental calcium in form of calcium carbonate daily cholecalciferol (vitamin D)60,000 IU per month for the next four months Arms: A, Cholecalciferol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose granules
Description: Drug: Lactose placebo Lactose placebo granules in identical sachet given weekly and two lactose tablets for first two months followed one sachet of placebo granules every month and two tablets of lactose containing placebo tablets taken daily for next four months
Study: NCT02554968

Intervention type: OTHER
Intervention: Questionnaires
Study: NCT03508648

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GTx-024
Description: Subjects will not be provided with any study treatments and will be off-drug during this extension study. Intervention was administered during study G201002.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GTx-024
Description: Subjects will not be provided with any study treatments and will be off-drug during this extension study. Intervention was administered during study G201002.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Subjects will not be provided with any study treatments and will be off-drug during this extension study. Intervention was administered during study G201002.
Study: NCT03977519

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MA
Description: Huatuo Brand needles (0.30×25mm,0.30×40mm or 0.30×75mm) will be used.Participants will receive manual acupuncture for 30 minutes each time.After acupuncture,we will twist the needles every 10 minutes for about 30 seconds.The patients will be treated in their first day of dysmenorrhea, once a day for three consecutive days. And the treatments will last for three consecutive menstrual cycles.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: Huatuo Brand electrode patch (50mm×50mm) and the SDZ-V EA apparatus (Suzhou Medical Appliance) will be used.Participants will receive transcutaneous electric nerve stimulation for 30 minutes each time.They will be treated in their first day of dysmenorrhea, once a day for three consecutive days. And the treatments will last for three consecutive menstrual cycles.
Study: NCT00743366

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Marijuana
Description: 0,6.2% THC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marijuana
Description: 0,6.2% THC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: 200 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Study: NCT02137161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone+Tobramycin eye drop
Description: dexamethasone 0.1% and tobramycin 0.3% ophthalmic suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone+Tobramycin eye drop
Description: dexamethasone 0.1% and tobramycin 0.3% ophthalmic suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromfenac eye drop
Description: bromfenac ophthalmic solution 0.09%
Study: NCT02739282

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Systematic therapeutic drug monitoring
Description: Blood samples with antiepileptic drug level measurement
Study: NCT02332590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for sarilumab)
Description: Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for adalimumab)
Description: Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
Study: NCT02446158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Description: The intervention group received daily cleaning of the exit site and application of 4% chlorhexidine (Antigerm Solution, Shining BioMedical Com. Ltd) with a swab. The chlorhexidine was rinsed off after 3 min of air drying and then gauze was applied.
Study: NCT02063126

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ReConnect (NADH plus CoQ10)
Description: ReConnect supplementation (NADH: 20 mg/day plus CoQ10: 200mg/day) divided into two daily dose ( 2 tablets/ before breakfast and 2 tablets/ before lunch)~Placebo supplementation divided into two daily dose ( 2 tablets/ before breakfast and 2 tablets/ before lunch)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo (phosphoserine/serine plus vitamin C) supplementation divided in two daily doses (2 tablets/before brekfast and 2 tablets/before lunch)
Study: NCT02183987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Knowledge Translation Intervention
Description: 1. Access to CSN guidelines, \& provider- \& patient-directed infographics recommending an intent-to-defer dialysis initiation strategy will be displayed in prominent clinic wall space \& disseminated to patients.~2. Educational whiteboard video will be made available as a resource for clinic staff \& patients.~3. Each clinic will receive reports from the Canadian Organ Replacement Register (CORR) outlining the proportion of patients followed by a Nephrologist (\>3 months) starting dialysis early (eGFR \>10.5 ml/min), for all incident dialysis patients from the clinic, with provincial \& national average comparisons. These reports, \& the CSN guideline on timing of dialysis initiation recommendation, will be delivered to the medical lead for each CKD clinic.~4. Each clinic will receive an in-person visit from one of the study investigators/collaborators highlighting the clinical practice guidelines \& evidence supporting an intent-to-defer strategy, \& will receive follow-up.
Study: NCT02077166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Study: NCT02977780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temzolomide capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Temzolomide capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Neratinib tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBS10072S
Description: QBS10072S administered intravenously
Study: NCT04568304

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toripalimab Injection
Description: Toripalimab Injection 240 mg iv infusion on Day 1 of each 3-week cycle. The cumulative duration of Toripalimab Injection is up to 2 years.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine Hydrochloride for Injection
Description: Gemcitabine 1000mg/㎡ iv infusion, on Day 1 and Day 8 of each cycle, each treatment cycle is 3 weeks.~The chemotherapy regimen will be administered for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride for Injection
Description: Gemcitabine 1000mg/㎡ iv infusion, on Day 1 and Day 8 of each cycle, each treatment cycle is 3 weeks.~The chemotherapy regimen will be administered for 6 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin for Injection / Carboplatin Injection
Description: Cisplatin 70mg/㎡ iv infusion, on Day 1 or Day 2 of each cycle, each treatment cycle is 3 weeks.~Carboplatin AUC 4.5 iv infusion, on Day 1 or Day 2 of each cycle, each treatment cycle is 3 weeks.~The chemotherapy regimen will be administered for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin for Injection / Carboplatin Injection
Description: Cisplatin 70mg/㎡ iv infusion, on Day 1 or Day 2 of each cycle, each treatment cycle is 3 weeks.~Carboplatin AUC 4.5 iv infusion, on Day 1 or Day 2 of each cycle, each treatment cycle is 3 weeks.~The chemotherapy regimen will be administered for 6 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo iv infusion on Day 1 of each 3-week cycle. The cumulative duration of placebo is up to 2 years.
Study: NCT01026116

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 75 mg/m2 every-3-week for four cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 75 mg/m2 every-3-week for four cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600 mg/m2 every-3-week for four cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2 every-3-week for four cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m2 every-3-week for four cycles followed by weekly paclitaxel (80 mg/m2) for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m2 every-3-week for four cycles followed by weekly paclitaxel (80 mg/m2) for 12 weeks
Study: NCT02101554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ages 7-11
Description: Oral/Capsule, once per day or twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 6 week Maintenance Treatment duration.
Study: NCT02077166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study: NCT03827122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Description: Experimental group we will use BTX-A administration group. All patients (Male/Female) with bruxism associated with chronic pain in masseter muscles bilaterally Patients will have treatment with 20 units of BOTOX, (Allergan Inc.) per side will be injected at three points into masseter muscle bilaterally.
Study: NCT01261338

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: olestra
Description: non-absorbable dietary fat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olestra
Description: non-absorbable dietary fat
Study: NCT02101554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ages 12-17
Description: Oral/Capsule, once per day or twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 6 week Maintenance Treatment duration.
Study: NCT03503266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] MT-7117
Description: 14-C MT-7117
Study: NCT02190539

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Homeopathic treatment
Description: Remedies are sold over the counter without a physician prescription (approved by the Israeli Ministry of Health). No toxicity or side effects are expected to be observed, potencies (dilutions) of substances beyond 7C (7 dilutions, each 1:100) do not contain a sufficient number of molecules of the original material to be pharmacologically active. Since the remedies being used in this trial are diluted at 30c and 200c, levels that are way beyond Avogrado's number, so no original material is expected to be found. This fact was verified utilizing high pressure liquid chromatography (HPLC) method. Due to those facts, most scientists do not accept that these remedies have any biological effects and consign any positive response to the placebo effect.
Study: NCT04598867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD-008-0045
Description: CD-008-0045 20 mg capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Afobazol
Description: Afobazol 10 mg tabletes
Study: NCT01515748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel (XRP6976)
Description: Pharmaceutical form:solution for infusion Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin (SR96669)
Description: Pharmaceutical form:solution for infusion Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 (1-(2-tetrahydrofuryl)-5-fluorouracil + 5-chloro-2, 4-dihydroxypyridine (CDHP) (Gimeracil) + Oxo (Oteracil)
Description: Pharmaceutical form:Tablet Route of administration: Oral

Intervention type: DRUG
Group type: OTHER
Intervention: S-1 (1-(2-tetrahydrofuryl)-5-fluorouracil + 5-chloro-2, 4-dihydroxypyridine (CDHP) (Gimeracil) + Oxo (Oteracil)
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study: NCT04250181

Intervention type: OTHER
Intervention: RF ablation of atrial fibrillation
Description: Comparison of standard, 40W and 50W RF energy setting for ablation of atrial fibrillation

Intervention type: OTHER
Intervention: RF ablation of atrial fibrillation
Description: Comparison of standard, 40W and 50W RF energy setting for ablation of atrial fibrillation

Intervention type: OTHER
Intervention: RF ablation of atrial fibrillation
Description: Comparison of standard, 40W and 50W RF energy setting for ablation of atrial fibrillation
Study: NCT03538834

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cod meal from residual material
Description: Cod meal from residual material, 8 g protein daily for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Placebo
Study: NCT02126579

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide Vaccine (LPV7) + Tetanus peptide
Description: 1.5 mL administered half intradermally and half subcutaneously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide Vaccine (LPV7) + Tetanus peptide
Description: 1.5 mL administered half intradermally and half subcutaneously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide Vaccine (LPV7) + Tetanus peptide
Description: 1.5 mL administered half intradermally and half subcutaneously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide Vaccine (LPV7) + Tetanus peptide
Description: 1.5 mL administered half intradermally and half subcutaneously.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PolyICLC
Description: 1 mL administered half intradermally and half subcutaneously

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PolyICLC
Description: 1 mL administered half intradermally and half subcutaneously

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PolyICLC
Description: 1 mL administered half intradermally and half subcutaneously

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PolyICLC
Description: 1 mL administered half intradermally and half subcutaneously

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PolyICLC
Description: 1 mL administered half intradermally and half subcutaneously

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resiquimod
Description: 500 mg applied to vaccine site after vaccine administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resiquimod
Description: 500 mg applied to vaccine site after vaccine administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resiquimod
Description: 500 mg applied to vaccine site after vaccine administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resiquimod
Description: 500 mg applied to vaccine site after vaccine administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IFA
Description: 2 mL administered half intradermally and half subcutaneously

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IFA
Description: 2 mL administered half intradermally and half subcutaneously

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IFA
Description: 2 mL administered half intradermally and half subcutaneously

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IFA
Description: 2 mL administered half intradermally and half subcutaneously

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IFA
Description: 2 mL administered half intradermally and half subcutaneously
Study: NCT01398618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-month rifampin vs. 9-month isoniazid
Description: In the 4M-RMP group, enrolled subjects received 600 mg rifampin daily for 4 months. In the 9M-INH group, enrolled subjects received 300 mg isoniazid daily for 9 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4-month rifampin vs. 9-month isoniazid
Description: In the 4M-RMP group, enrolled subjects received 600 mg rifampin daily for 4 months. In the 9M-INH group, enrolled subjects received 300 mg isoniazid daily for 9 months.
Study: NCT00675012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGR-hTNF
Description: iv 0.8 or 45 mcg/sqm q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: iv q3W 100 mg/sqm 60 minutes after NGR-hTNF infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: orally 825 mg/sqm 2qDx14
Study: NCT01333046

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antigen-Escalation Stage
Description: Antigen-Escalation Stage~Each patient will receive 2 injections at the same dose (5 x 10\^6 cells/m2), 28 days apart, according to the following schedules:~Schedule One:~* Day 0: PRAME-specific T cells~* Day 28: PRAME- and SSX-specific T cells~Schedule Two:~* Day 0: PRAME- and SSX-specific T cells~* Day 28: PRAME/SSX/MAGE-specific T cells~Schedule Three:~* Day 0: PRAME/SSX/MAGE-specific T cells~* Day 28: PRAME/SSX/MAGE/NY-ESO specific T cells~Schedule Four:~* Day 0: PRAME/SSX/MAGE/NY-ESO specific T cells~* Day 28: PRAME/SSX/MAGE/NY-ESO/Survivin-specific T cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose-Escalation Stage
Description: Dose-Escalation Stage~Three different dosing schedules will be evaluated. Each patient will receive 2 injections at the same dose, 14 days apart, according to the following dosing schedules:~DL1: Day 0 and Day 14: 5 x 10\^6 cells/m\^2~DL2: Day 0 and Day 14: 1 x 10\^7 cells/m\^2~DL3: Day 0 and Day 14: 2 x 10\^7 cells/m\^2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: azacytidine and multiTAA T cells Stage
Description: Up to 15 patients will be treated with 3 cycles of aza at a dose of 75 mg/m2 I.V. administered for 5 days/cycle followed, within 28 days of the last aza dose, by two infusions (on Day 0 and Day 14) of multi-TAA specific CTLs at a fixed dose of 1x10\^7 cells/m2. If drug-related myelosuppression occurs aza dosing will be modified, according to the following:~1. ANC \>1,000 or Platelets \>50,000 (or any other grade I AE attributable to aza)~   Adjustment: None~2. ANC 500-1000 or Platelets 25,000-50,000 (or any other grade II-III AE attributable to aza)~   Adjustment: 50% dose reduction~3. ANC \<500 or any episode of febrile neutropenia or platelets \<25,000 or any episode of bleeding attributed to thrombocytopenia (or any other grade IV or higher AE attributable to aza)~Adjustment: Discontinue drug, can proceed with CTL infusion if eligible within 28 days of last aza infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pediatric multiTAA T cells Stage
Description: Patients \< 18 years old will receive two infusions (on Day 0 and Day 14) of multi-TAA specific T cells at a fixed dose of 1x10\^7 cells/m2. We will enroll and infuse at least 5 adolescents on the pediatric arm before opening to all patients.
Study: NCT06094725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant
Description: Relacorilant 300 mg (3 X 100 mg softgel capsules) for oral administration
Study: NCT03001284

Intervention type: OTHER
Intervention: NO intervention

Intervention type: OTHER
Intervention: NO intervention
Study: NCT01811082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme A
Description: Coenzyme A 400mg per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantethine
Description: Pantethine 600mg per day.
Study: NCT00553696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 60 mg/m2 on day 1 of each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 80 mg/m2 on days 1-21 of each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib 25 mg, 37.5 mg and 50 mg daily S-1 80 mg/m2 on days 1-21 of each 28 day cycle Cisplatin 60 mg/m2 on day 1 of each 28 day cycle
Study: NCT02603081

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPI-1005
Description: Ebselen is a small molecule mimic and inducer of glutathione peroxidase (GPx). GPx reduces reactive oxygen species by the binding of free radicals to its selenium moiety. Ebselen has strong anti-inflammatory characteristics.
Study: NCT03903484

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deprescribing toolbox and intervention
Description: Pharmacist-led deprescribing plan with the patient which will include the patient's deprescribing goals. The intervention advocates for deprescribing according to recognized algorithms and guidelines which will be included in a resource toolbox/website.